Статья
Эректильная дисфункция и сердечно-сосудистые заболевания: новый взгляд на старую проблему
Большое количество экспериментальных и клинических данных, указывают на то, что артериогенная форма эректильной дисфункции (ЭД) является не поздним осложнением сердечно-сосудистых заболеваний (ССЗ), а ранним проявлением системной сосудистой патологии. Важным механизмом, объединяющим ЭД и ССЗ, служит эндотелиальная дисфункция, поражающая различные сосудистые системы и в т.ч. эндотелий кавернозных тел. Последнее снижает синтез и/или биодоступность оксида азота, являющегося основным медиатором эрекции. Системный характер сосудистого поражения у больных артериогенной ЭД подтверждается наличием у них признаков эндотелиальной дисфункции крупных артериальных сосудов и объясняет повышенную вероятность наличия скрытой ишемической болезни сердца. Это подчеркивает важность активного раннего выявления ЭД не только врачами-урологами, но также кардиологами и терапевтами, для которых наличие у больного ЭД должно свидетельствовать о необходимости более тщательного обследования и раннего начала лечения.
1. NIH Consensus development conference statement. NIH consensus development panel on impotence. Int J Impot Res 1993; 4: 181-284.
2. Shah J. Erectile dysfunction through the ages. BJU Int 2002; 90: 433-41.
3. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003; 89: 251-4.
4. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
5. Braun M, Wassner G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the “Cologne Male Survey”. Int J Impot Res 2000; 12(6): 305-11.
6. Parazzini F, Menchini FF, Bortolotti A, et al. Frequency and determinants of erectile dysfunction in Italy. Eur Urol 2000; 37: 43-9.
7. Chew KK, Earle CM, Stuckey BGA, et al. Erectile dysfunction in general medicine practice: prevalence and clinical correlates. Int J Impot Res 2000; 12: 41-5.
8. Roumeguere T, Wespes E, Carpentier Y, et al. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol 2003; 44: 355-9.
9. Wabrek AJ, Burchell C. Male sexual dysfunction associated with coronary artery disease. Arch Sexual Behavior 1980; 9: 69-75.
10. Agarwal A, Jain DC. Male sexual dysfunction after stroke. J Ass Physicians India 1989; 37: 505-8.
11. Virag R, Bouilly P. Is impotence an arterial disease? A study of arterial risk factors in 440 impotence men. Lancet 1985; 322: 181-4.
12. Montorsi P, Montorsi F, Schulman CC. Is erectile dysfunction the “tip of the iceberg” of a systemic vascular disorder? Eur Urol 2003; 44: 352-4.
13. Montorsi F, Briganti A, Salonia A, et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003; 44: 360-5.
14. Little WC, Constantinescu M, Applegate RS, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988; 78: 1157-66.
15. Duff GL, McMillan GC. Pathology of atherosclerosis. Am J Med 1951; 11: 92-108.
16. Lea AP, Bryson HM, Balfour JA. Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction. Drugs Aging 1996; 8: 56-74.
17. Montorsi F, Salonia A, Deho F, et al. Pharmacological management of erectile dysfunction. BJU Int 2003; 91: 446-54.
18. Pourmand G, Alidaee MR, Rasuli S, et al. Do cigarette smokers with erectile dysfunction benefit from stopping? a prospective study. BJU Int 2004; 94: 1310-3.
19. Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004; 291(24): 2978-84.
20. Saltzman EA, Guay AT, Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: A clinical observation. J Urol 2004; 172: 255-8.
21. Bivalacqua TJ, Usta MF, Champion HC, et al. Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J Androl 2003; 24(6) Suppl: S17-37.
22. Иванова О.В., Соболева Г.Н., Карпов Ю.А. Эндотелиальная дисфункция - важный этап развития атеросклеротического поражения сосудов. Тер архив 1997; 6: 75-8.
23. Vane J, Anggard E, Botting R. Regulatory function of the vascular endothelium. N Engl J Med 1990; 323: 27-36.
24. Liao JK. Endothelium and acute coronary syndromes. Clin Chem 1998; 44: 1799-808.
25. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease. N Engl J Med 1992; 326: 242-50.
26. Kanani PM, Sinkey CA, Browning RL, et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocysteinemia in humans. Circulation 1999; 100: 1161-8.
27. Plotnick GD, Corretti MC, Vogel RA. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA 1997; 278: 1682-6.
28. Williams SB, Goldfine AB, Timini FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998; 97: 1695-701.
29. Vanhoutte PM. Endothelial Control of Vasomotor Function. Circ J 2003; 67: 572-5.
30. De Graaf JC, Banga JD, Moncada S, et al. Nitric oxide inhibitor of platelet adhesion under flow conditions. Circulation 1992; 85: 2284-90.
31. Tomita H, Egashira K, Kubo-Inoue M, et al. Ingibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arterioscler Thromb Vasc Biol 1998; 18: 1456-64.
32. Burnett AL, Lowenstein CJ, Bredt DS, et al. Nitric oxide: a physiologic mediator of penile erection. Science 1991; 257: 401-3.
33. Arnold WP, Mittal CK, Katsuki S, et al. Nitric oxide activates guanylate cyclase and increases guanosine 3,5’-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci 1977; 74: 3203-7.
34. Rybalkin SD, Yan C, Bornfeldt KE, et al. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 2003; 93: 280-91.
35. Hurt KJ, Musicki B, Palese MA, et al. Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci USA 2002; 99: 4061-8.
36. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995; 75: 191-236.
37. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100: 2153-7.
38. Bivalacqua TJ, Hellstrom WJ. Potential application of gene therapy for the treatment of erectile dysfunction. J Androl 2001; 22: 183-90.
39. Cartledge JJ, Eardley 1, Morrison JE Impairment of corpus caveniosal smooth muscle relaxation by glycosylated human haemoglobin. BJU Int 2000; 85: 735-41.
40. Kim SC, Kim IK, Seo KK, et al. Involvement of superoxide radical in the impaired endothelium-dependent relaxation of cavernous smooth muscle in hypercholesterolemic rabbits. Urol Res 1997; 25: 341-6.
41. Ryu JK, Kim DY, Lee T, et al. The role of free radical in the pathogenesis of impotence in streptozotocin-induced diabetic rats. Yonsei Med J 2003; 44: 236-41.
42. Ferrini M, Magee TR, Vernet D, et al. Aging-related expression of inducible nitric oxide synthase and markers of tissue damage in the rat penis. Biol Reprod 2001; 64: 974-82.
43. Kuvin JT, Karas RH. Clinical utility of endothelial function testing. Ready for prime time? Circulation 2003; 107: 3243-7.
44. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046-51.
45. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.
46. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995; 91: 1314-9.
47. Cooke JP, Rossitch E, Andon N, et al. Flow activates an endothelium potassium channel to release an endogenous nitrovasodilator. J Clin Invest 1991; 88: 1663-7.
48. Celermajer DS. Endothelial dysfunction: Does it matter? Is it reversible? JACC 1997; 30: 325-33.
49. Anderson T, Uehata A, Gerhard M, et al. Close relation of endothelial function in the human coronary and peripheral circulations. JACC 1995; 26: 1235-41.
50. Gaeta G, De Michele M, Guomo S, et al. Arterial abnormalities in the offspring of patients with premature myocardial infarction. N Engl J Med 2000; 343: 840-6.
51. Neunteufl T, Heher S, Katzenschlager R, et al. Long-term prognostic value of flow-mediated dilation in the brachial artery in patients with chest pain. Am J Cardiol 2000; 86: 207-10.
52. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191-6.
53. Gokce N, Keaney J, Hunter L, et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function. Circulation 2002; 105: 1567-72.
54. Virag R. Flow-dependent dilatation of the cavernous artery. A potential test of penile NO content. J Mal Vasc 2002; 27(4): 214-7.
55. Kaiser DR, Billups K, Mason C, et al. Impaired brachial artery endothelium-dependent and –independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. JACC 2004; 43: 179-84.
56. Kawanishi Y, Lee KS, Kimura K, et al. Screening of ischemic heart disease with cavernous artery blood flow in erectile dysfunctional patients. Int J Impot Res 2001; 13: 100-5.
57. Kim SW, Paick JS, Park DW, et al. Potential predictors of asymptomatic ischemic heart disease in patients with vasculogenic erectile dysfunction. Urology 2001; 58: 441-5.